Imugene
Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Supported by a team of international cancer experts, the company aims to transform and improve cancer treatment and patients' lives through innovative platform technologies and a robust pipeline including CAR T cell therapy, oncolytic virus, and B-cell immunotherapies.
Industries
Nr. of Employees
medium (51-250)
Imugene
Millers Point, New South Wales, Australia
Patents
Products
Allogeneic CD19-targeting CAR T candidate
An off‑the‑shelf allogeneic CAR T cell therapy candidate developed to target CD19 for treatment of B‑cell blood cancers; progressed into early‑phase clinical dosing (Phase 1b for relapsed DLBCL described).
Oncolytic vaccinia-derived virus with imaging reporter
A recombinant oncolytic vaccinia-derived viral candidate engineered for improved safety and potency and encoded with an imaging reporter gene to enable in vivo tracking of viral distribution.
Virus-mediated tumour antigen delivery to sensitize solid tumours
A therapeutic approach using oncolytic viruses to express tumour antigen on cancer cells to promote targeted cellular immunotherapy responses (e.g., enabling CAR T activity in solid tumours).
B‑cell vaccine candidates targeting HER2 and PD‑1
B‑cell immunotherapy vaccine candidates designed to elicit endogenous antibody responses against validated oncology targets such as HER2 and PD‑1 for therapeutic application.
onCARlytics (CF33-CD19)
A novel immunotherapy utilising the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells, promoting combination therapies with CD19 targeting agents against solid tumours.
PD1-Vaxx
PD1-Vaxx is a B-cell immunotherapy which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, producing an anticancer effect similar to immune checkpoint inhibitor monoclonal antibodies.
Allogeneic CD19-targeting CAR T candidate
An off‑the‑shelf allogeneic CAR T cell therapy candidate developed to target CD19 for treatment of B‑cell blood cancers; progressed into early‑phase clinical dosing (Phase 1b for relapsed DLBCL described).
Oncolytic vaccinia-derived virus with imaging reporter
A recombinant oncolytic vaccinia-derived viral candidate engineered for improved safety and potency and encoded with an imaging reporter gene to enable in vivo tracking of viral distribution.
Virus-mediated tumour antigen delivery to sensitize solid tumours
A therapeutic approach using oncolytic viruses to express tumour antigen on cancer cells to promote targeted cellular immunotherapy responses (e.g., enabling CAR T activity in solid tumours).
B‑cell vaccine candidates targeting HER2 and PD‑1
B‑cell immunotherapy vaccine candidates designed to elicit endogenous antibody responses against validated oncology targets such as HER2 and PD‑1 for therapeutic application.
onCARlytics (CF33-CD19)
A novel immunotherapy utilising the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells, promoting combination therapies with CD19 targeting agents against solid tumours.
PD1-Vaxx
PD1-Vaxx is a B-cell immunotherapy which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, producing an anticancer effect similar to immune checkpoint inhibitor monoclonal antibodies.
Services
Sponsor and manage multi-site clinical trials for early‑phase oncology candidates across blood cancers and solid tumours, coordinating with investigators and clinical sites.
Establish and operate research collaborations with academic centres and external laboratories to advance preclinical development and clinical translation of immunotherapies.
Sponsor and manage multi-site clinical trials for early‑phase oncology candidates across blood cancers and solid tumours, coordinating with investigators and clinical sites.
Establish and operate research collaborations with academic centres and external laboratories to advance preclinical development and clinical translation of immunotherapies.
Expertise Areas
- Immuno-oncology
- Cell therapy development (allogeneic CAR T)
- Oncolytic virotherapy
- Cancer vaccine development (B‑cell vaccines)
Key Technologies
- Allogeneic CAR T cell therapy
- CD19-targeted cellular immunotherapy
- Oncolytic vaccinia-derived viral vectors
- Viral transgene expression (imaging reporter/hNIS)